Understanding the Role of Institutional Review Boards (IRBs) in Clinical Trials

Institutional Review Boards (IRBs)—also known as Ethics Committees (ECs) in many regions—play a pivotal role in safeguarding the rights, safety, and well-being of participants in clinical trials. They are essential to the ethical conduct and regulatory compliance of biomedical research. This guide explores the structure, responsibilities, and impact of IRBs, and how investigators and sponsors can work effectively with them throughout a trial.

What is an IRB?

An IRB is an independent committee formally designated to review and monitor research involving human subjects. According to USFDA regulations (21 CFR Part 56) and ICH-GCP E6(R2), no clinical trial involving humans can begin without IRB approval.

• IRBs assess the ethical acceptability of study protocols
• They ensure compliance with local laws, regulations, and ethical standards
• They serve as a protective oversight for clinical trial participants

Key Responsibilities of an IRB:

IRBs are entrusted with multiple critical responsibilities, including:

1. Review of Study Protocols: Assess scientific rationale, methodology, and participant impact
2. Review and Approval of Informed Consent Documents: Ensure clarity, readability, and accuracy
3. Ongoing Trial Monitoring: Periodic review of safety reports, deviations, and amendments
4. Risk-Benefit Assessment: Evaluate whether anticipated benefits justify potential risks
5. Review of Investigator Qualifications: Verify GCP training and experience
6. Protection of Vulnerable Populations: Scrutinize consent process and trial design for pediatric, geriatric, or cognitively impaired subjects

Refer to your site’s SOPs for IRB submissions for process consistency and compliance.

IRB Composition and Independence:

Per ICH-GCP and CDSCO guidelines, an IRB must be multidisciplinary and include:

• At least five members with diverse backgrounds
• One member from a non-scientific area (e.g., legal, ethics)
• One member unaffiliated with the institution (community representative)
• At least one woman

This diversity ensures impartiality, community perspective, and robust ethical deliberation.

IRB Review Types:

IRBs conduct reviews based on study complexity and risk level:

• Full Board Review: Required for studies with greater than minimal risk
• Expedited Review: For minimal-risk studies or minor amendments
• Exempt Review: Reserved for specific categories defined under regulatory frameworks

The type of review determines documentation requirements and timelines.

IRB Submission Requirements:

Investigators must submit a complete application package including:

• Study protocol and synopsis
• Informed Consent Form (ICF) and translations
• Investigator’s Brochure (IB)
• PI’s CV and GCP training certificate
• Case Report Forms (CRFs), recruitment materials
• Insurance certificate (if applicable)
• Institutional cover letter and EC fee receipt (if applicable)

IRB review timelines and formats may vary by country or institution. Best practices are available via StabilityStudies.in.

IRB Approval Letter and Conditions:

Following review, the IRB may:

• Approve the study without modifications
• Request clarifications or amendments before approval
• Reject the study due to ethical or scientific concerns

The IRB approval letter will include conditions such as submission of safety reports, re-approvals for long studies, and prior approval for amendments.

Ongoing Interaction with IRBs:

IRB oversight continues throughout the study. Investigators are required to:

• Submit annual status reports or renewals for continuing review
• Report protocol deviations, serious adverse events (SAEs), or unanticipated risks
• Obtain prior approval for protocol amendments
• Notify IRB of trial closure with final report

All IRB communications must be documented in the Investigator Site File (ISF) and audit-ready per GMP documentation expectations.

IRB vs Ethics Committee (EC):

Though used interchangeably, IRBs and ECs differ slightly based on geography:

• IRB: Common term in the U.S. under FDA oversight
• EC: Term used in India, EU, and other regions

Both function similarly and adhere to ICH-GCP principles, but documentation and composition requirements may vary slightly.

Training and Working with IRBs:

Investigators and site teams must be trained on:

• IRB submission processes
• Timelines and documentation standards
• Responding to IRB queries
• Maintaining communication logs and audit trails

Refer to validation master plans and sponsor SOPs for IRB collaboration guidance.

Conclusion:

Institutional Review Boards serve as ethical gatekeepers in clinical research, ensuring participant safety and study integrity. Their oversight spans from study initiation to completion, requiring ongoing interaction and compliance from investigators. By understanding IRB roles, submission expectations, and documentation requirements, clinical research professionals can contribute to ethically sound and regulation-compliant trials.

How to Revise Informed Consent Following Protocol Amendments in Clinical Trials

In the lifecycle of a clinical trial, changes to the protocol are common—whether due to safety findings, scientific advancements, regulatory updates, or operational needs. When such amendments affect the rights, safety, or well-being of participants, the informed consent form (ICF) must be revised and participants must be re-consented. This guide walks you through the why, when, and how of revising informed consent in line with regulatory requirements and best practices.

Why Re-Consent is Necessary After Protocol Changes:

Protocol amendments can impact participants in several ways. These may include changes in:

• Dosage, administration frequency, or treatment duration
• Inclusion/exclusion criteria
• Risk profile or new adverse events
• Trial procedures or frequency of visits
• Withdrawal rights or compensation clauses

Ethically, participants must be informed of these changes and have the opportunity to continue or withdraw based on the updated protocol. This aligns with ICH-GCP E6(R2), USFDA, and CDSCO guidelines.

When Should Informed Consent Be Revised?

Informed consent should be updated and re-administered when amendments:

• Introduce new risks or benefits
• Change study procedures involving participant commitment
• Modify key ethical considerations (e.g., inclusion criteria)
• Are flagged by regulatory authorities or ethics committees

Minor administrative changes (e.g., typos or contact details) may not require re-consent but should still be version-controlled.

Steps to Revise and Re-Implement Informed Consent:

1. Identify Changes That Require Re-Consent:

Collaborate with medical monitors, regulatory affairs, and safety teams to determine if an amendment warrants participant re-consent.

2. Draft Revised ICF:

• Use a clear, non-technical language to explain the changes
• Highlight modifications in risks, procedures, or rights
• Update version number and date prominently

Refer to your pharma SOP documentation on ICF development and version control.

3. Ethics Committee Approval:

Submit the revised ICF and protocol amendment to the Institutional Review Board (IRB) or Ethics Committee (EC). Provide:

• Tracked and clean versions of the revised ICF
• Rationale for the changes
• Communication plan for ongoing participants

No re-consenting can occur before EC approval.

4. Train Site Staff on New Procedures:

Ensure that investigators and site coordinators understand:

• The nature of the changes
• How to explain revisions to participants
• Documentation requirements and version use

Update site training logs and delegation logs accordingly to remain compliant with GMP compliance expectations.

5. Re-Consent Process with Participants:

Conduct one-on-one sessions with each enrolled subject. Ensure that:

• Revised consent is provided in the participant’s preferred language
• Time is given to review and ask questions
• A new signature is obtained on the revised ICF
• The reason for re-consent is documented in source notes

Witnesses are required for illiterate subjects or when required by protocol or EC.

Documentation and Version Control:

Accurate documentation of consent revisions is crucial for inspection readiness:

• Label revised ICFs clearly with version and date
• Maintain both signed old and new ICFs in the ISF
• Use validation master plan principles to track consent workflow
• Update the Informed Consent Log and screening checklist

Handling Participants Who Refuse Re-Consent:

If a participant chooses not to continue under the revised protocol:

• Document the reason and date of withdrawal
• Report to the sponsor and Ethics Committee
• Ensure any follow-up per protocol for early withdrawals is completed

This decision must be respected and must not affect the subject’s access to standard medical care.

Managing eConsent During Protocol Amendments:

If using an eConsent system:

• Update digital templates with new version and content
• Re-validate system outputs per clinical trial documentation standards
• Re-capture digital signatures and audit trails

Common Audit Observations Related to Re-Consent:

• Using outdated ICF versions for new enrollments
• Failure to re-consent enrolled participants after significant amendments
• Missing EC approval for revised ICF
• Poorly documented re-consent process in source notes

These issues can lead to findings in inspections by EMA, FDA, or national agencies.

Checklist for Re-Consenting Participants:

1. Confirm need for re-consent based on amendment
2. Prepare revised ICF (translated if needed)
3. Submit to and obtain EC approval
4. Train site staff on the update
5. Conduct re-consent sessions
6. Update logs and ISF with new documentation
7. Ensure no old version is used after cutoff date

Conclusion:

Re-consenting participants after protocol amendments is not just a regulatory requirement—it is a matter of ethical transparency and participant protection. A well-managed re-consent process upholds the integrity of the study and fosters trust between participants and researchers. By following structured SOPs, ensuring proper documentation, and engaging with ethics committees, clinical trial teams can seamlessly manage consent revisions across the study lifecycle.